Sana Biotechnology, Inc. SANA R2KR3KPHARMA
Company Overview
Sana Biotechnology, Inc., a biotechnology company, focuses on utilizing engineered cells as medicines in the United States. It develops ex vivo and in vivo cell engineering platforms for various therapeutic areas with unmet treatment needs, including type 1 diabetes, B cell mediated autoimmune diseases, and oncology. The company's product pipeline includes UP421, a HIP-modified allogeneic primary islet cell product, which is in phase 1 clinical trial to treat type 1 diabetes; SC451, a HIP-modified, stem cell derived pancreatic islet cell therapy, which is in preclinical trial for the treatment of type 1 diabetes; SG293 and SG299, a CD8-targeted fusosome for the treatment of B cell hematologic malignancies and B cell mediated autoimmune diseases. The company has an option and license agreement with Beam Therapeutics Inc. for use of Beam's proprietary CRISPR Cas12b nuclease editing technology to research, develop, and commercialize engineered cell therapy products; and a license agreement with Harvard College to access certain intellectual property for the development of hypoimmune-modified cells. The company has a strategic collaboration with Mayo Clinic for the development of SC451, a hypoimmune-modified pancreatic islet cell therapy for type 1 diabetes. The company was formerly known as FD Therapeutics, Inc. and changed its name to Sana Biotechnology, Inc. in September 2018. Sana Biotechnology, Inc. was incorporated in 2018 and is headquartered in Seattle, Washington.
Growth & Price Performance
Stock Price Performance
| 1 Year: | +15.62% |
| 6 Months: | +22.22% |
| 3 Months: | +43.66% |
| 1 Month: | +12.90% |
Highlights auto-generated from reported financials and price data; not investment advice. Verify with official filings before acting.
- Price vs 50-DMAAbove
- Price vs 200-DMAAbove
- RSI (14)53.13 · Neutral
Auto-generated from price history and fundamentals; not investment advice.
Price Chart
Technical Trend
Computed from daily close history using EMA cross, slope, and RSI signals.
Note: intraday data is not stored locally. “Hourly” uses the most recent 10 daily candles as a short-term proxy.
Fundamental Growth Charts
No fundamental data available for this stock.
Interactive charts for Revenue, Net Income, EBITDA, Free Cash Flow, EPS, ROE, ROCE, Gross/Net/Operating Margin and more — switch metric and period using the dropdowns above. CAGR is computed across the displayed window (quarterly CAGR is annualised). Visual growth charts make it easy to spot multi-year compounding trends at a glance — far faster than reading raw numbers in a table.
PROS
No notable strengths flagged.
CONS
- Trading 35.0% below its 52-week high.
- In a downtrend (50-DMA below 200-DMA).
* The pros and cons are auto-generated from financial metrics.
Valuation
Growth (CAGR)
Profitability & Returns
Balance Sheet & Liquidity
Ownership
Financial Snapshot
Peer comparison
Peer companies in the same sector (Healthcare).
| # | Name | CMP $ | P/E | Mkt Cap | Div Yld % | ROCE % | ROE % | Rev CAGR 5Y % | Profit CAGR 5Y % |
|---|---|---|---|---|---|---|---|---|---|
| 1 | SANA Sana Biotechnology, Inc. R2KR3KPHARMA | 3.85 | -4.18 | $1.07B | 0.00% | -74.02% | -147.41% | - | - |
| 2 | LLY Eli Lilly and Company SPXR3KPHARMA | 1,149.36 | 38.57 | $1.02T | 0.58% | - | 102.29% | 7.20% | 11.41% |
| 3 | JNJ Johnson & Johnson SPXR3KPHARMA | 275.23 | 31.97 | $663.28B | 2.09% | 14.88% | 25.74% | 2.43% | 4.76% |
| 4 | ABBV AbbVie Inc. SPXR3KPHARMA | 256.46 | 72.45 | $453.19B | 2.84% | 10.47% | -129.24% | 1.75% | -29.06% |
| 5 | MRK Merck & Co., Inc. SPXR3KPHARMA | 150.33 | 120.26 | $371.29B | 2.65% | - | 34.70% | 5.64% | 10.01% |
| 6 | UNH UnitedHealth Group Incorporated SPXR3KPHARMA | 397.14 | 25.54 | $356.47B | 2.33% | 9.74% | 14.15% | 10.40% | 5.43% |
| 7 | NVS Novartis AG PHARMA | 159.99 | 24.20 | $304.10B | 3.03% | 21.09% | 30.35% | 9.25% | 26.22% |
| 8 | AZN AstraZeneca PLC NDXPHARMA | 162.70 | 24.36 | $252.33B | 1.98% | 15.97% | 21.96% | 9.82% | 45.96% |
| 9 | AMGN Amgen Inc. NDXSPXR3KPHARMA | 437.23 | 27.14 | $235.98B | 2.49% | 13.95% | 91.47% | 5.51% | 5.55% |
Financial Statements Quarterly Results · Profit & Loss · Balance Sheet · Cash Flows · Ratios
Quarterly Results
Figures in USD.
| Metric | Mar 2020 | Jun 2020 | Sep 2020 | Mar 2021 | Jun 2021 | Sep 2021 | Mar 2022 | Jun 2022 | Sep 2022 | Mar 2023 | Jun 2023 | Sep 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating Income | -33.27M | -87.91M | -51.64M | -180.75M | 18.55M | -83.43M | -31.68M | -72.90M | -86.19M | -84.05M | -116.29M | -2.18M | -110.72M | -49.37M | -61.76M | -50.63M | -94.97M | -43.52M | -48.61M |
| Net Income | -32.88M | -87.81M | -51.45M | -180.62M | 18.68M | -83.26M | -31.45M | -72.47M | -85.12M | -82.12M | -114.00M | 984.00K | -107.47M | -50.29M | -59.92M | -49.39M | -93.80M | -42.15M | -47.21M |
| Diluted EPS | - | -7.18 | - | - | 0.09 | -0.46 | -0.17 | -0.39 | -0.45 | -0.43 | -0.59 | 0.00 | -0.49 | -0.21 | -0.25 | -0.21 | -0.39 | -0.16 | -0.17 |
| R&D Expense | 27.32M | 29.99M | 40.06M | 41.88M | 45.00M | 53.24M | 72.69M | 72.54M | 76.73M | 67.17M | 73.04M | 65.61M | 56.45M | 60.87M | 53.21M | 37.19M | 29.76M | 30.11M | 28.72M |
Profit & Loss (Annual)
Figures in USD.
| Metric | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|
| Operating Income | -141.15M | -286.15M | -356.91M | -272.56M | -293.14M | -272.72M | -250.32M |
| Net Income | -130.78M | -285.31M | -355.93M | -269.48M | -283.25M | -266.76M | -244.17M |
| Diluted EPS | - | -21.92 | -2.14 | -1.43 | -1.46 | -1.16 | -0.96 |
| R&D Expense | 99.59M | 132.94M | 248.63M | 285.88M | 261.81M | 215.67M | 131.98M |
Balance Sheet (Annual)
Figures in USD.
| Metric | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|
| Total Assets | - | - | 730.30M | 1.13B | 822.72M | 565.30M | 501.02M | 416.89M |
| Total Equity | -13.19M | -142.54M | -421.18M | 728.50M | 499.31M | 287.51M | 250.50M | 160.88M |
| Cash & Equivalents | - | - | 124.81M | 253.03M | 176.76M | 133.52M | 127.57M | 71.87M |
| Total Liabilities | - | - | 298.58M | 400.90M | 323.40M | 277.79M | 250.52M | 256.01M |
| Current Liabilities | - | - | 31.45M | 99.23M | 111.50M | 64.49M | 45.43M | 78.73M |
Cash Flows (Annual)
Figures in USD.
| Metric | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|
| Operating Cash Flow | -85.52M | -137.98M | -251.05M | -290.05M | -253.58M | -223.15M | -143.83M |
| Investing Cash Flow | -87.86M | -252.56M | -245.80M | 210.56M | 172.01M | 17.45M | -40.24M |
| Financing Cash Flow | 223.74M | 435.69M | 631.75M | 4.91M | 31.65M | 199.75M | 128.73M |
| Capital Expenditure | -26.12M | -23.87M | -29.86M | -20.88M | -20.03M | -33.43M | -938.00K |
| Free Cash Flow | -111.64M | -161.85M | -280.92M | -310.93M | -273.61M | -256.58M | -144.77M |
Ratios (Annual)
Figures in %.
| Metric | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|
| Gross Margin % | - | - | - | - | - | - | - |
| Operating Margin % | - | - | - | - | - | - | - |
| Net Margin % | - | - | - | - | - | - | - |
| ROE % | 91.7% | 67.7% | -48.9% | -54.0% | -98.5% | -106.5% | -151.8% |
| ROCE % | - | -40.9% | -34.6% | -38.3% | -58.5% | -59.9% | -74.0% |
Shareholding Pattern
Top Institutional Holders
| # | Holder | % Held | Shares | Value |
|---|---|---|---|---|
| 1 | FMR, LLC | 12.50% | 37.43M | $147.10M |
| 2 | Flagship Pioneering LLC | 8.35% | 25.00M | $98.26M |
| 3 | RA Capital Management, L.P. | 6.26% | 18.75M | $73.69M |
| 4 | Blackrock Inc. | 5.57% | 16.68M | $65.53M |
| 5 | State Street Corporation | 3.74% | 11.20M | $44.03M |
| 6 | Canada Pension Plan Investment Board | 3.41% | 10.22M | $40.16M |
| 7 | Vanguard Capital Management LLC | 2.80% | 8.38M | $32.92M |
| 8 | Bank of America Corporation | 1.92% | 5.75M | $22.59M |
| 9 | Geode Capital Management, LLC | 1.56% | 4.68M | $18.38M |
| 10 | Marex Group Ltd. | 1.33% | 3.99M | $15.68M |
Analyst View
Analyst aggregate. Targets and ratings update periodically; not investment advice.
Latest News
Recent headlines for SANA
Sana Biotechnology to Present at September 2026 Investor Conferences
SEATTLE, Sept. 01, 2026 (GLOBE NEWSWIRE) -- Sana Biotechnology, Inc. (NASDAQ: SANA), a company focused on changing the possible for patients through engineered cells, today announced that it will webcast its presentations at four investor c…
Sana Biotechnology (SANA) Publishes 14 Month Diabetes Cell Therapy Results In NEJM
Sana Biotechnology (NasdaqGS:SANA) reported long term follow up data from an investigator sponsored study of its HIP modified islet cell therapy for type 1 diabetes. Results published in The New England Journal of Medicine highlighted safet…
Sana (SANA) Upgraded to Buy: Here's What You Should Know
Sana (SANA) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
Sana Biotechnology Announces Symposium Presentation at the European Association for the Study of Diabetes (EASD) Annual Meeting 2026
SEATTLE, July 01, 2026 (GLOBE NEWSWIRE) -- Sana Biotechnology, Inc. (NASDAQ: SANA), a company focused on changing the possible for patients through engineered cells, today announced a symposium presentation highlighting clinical data from a…
Sana Biotechnology Announces Sale of Approximately $69 Million of Shares Through its At-the-Market (ATM) Facility
SEATTLE , May 15, 2026 (GLOBE NEWSWIRE) -- Sana Biotechnology, Inc. (NASDAQ: SANA), a company focused on changing the possible for patients through engineered cells, today announced that it has sold an aggregate of 21,607,878 shares of the …
Sana Biotechnology Presents Preclinical Data for In Vivo CAR T Cell Therapy SG293 Surrogate Demonstrating Cell-Specific Delivery, Potent CAR T Cell Generation, and Deep B Cell Depletion in NHPs
Data presented at the American Society of Gene & Cell Therapy (ASGCT) 2026 Annual MeetingSEATTLE, May 12, 2026 (GLOBE NEWSWIRE) -- Sana Biotechnology, Inc. (NASDAQ: SANA), a company focused on changing the possible for patients through engi…
SANA — Frequently Asked Questions
What is the current share price of Sana Biotechnology, Inc. (SANA)?
As of 2026-09-07 16:24 PDT, Sana Biotechnology, Inc. (SANA) trades at $3.85 on NasdaqGS. Its 52-week range is $2.68 to $5.92.
What is the market capitalisation of SANA?
Sana Biotechnology, Inc. (SANA) has a market capitalisation of $1.07B on NasdaqGS.
What is the P/E ratio of SANA?
SANA trades at a trailing price-to-earnings (P/E) ratio of -4.18. The industry average P/E is 25.17. Its price-to-book (P/B) ratio is 7.96.
What is the return on equity (ROE) of SANA?
SANA has a return on equity (ROE) of -147.41%. Its return on capital employed (ROCE) is -74.02%.
Is SANA a good stock to buy?
This page provides a data-driven analysis of Sana Biotechnology, Inc. (SANA), including valuation ratios, profitability, growth trends, auto-generated pros and cons, peer comparison and AI exposure. Review these fundamentals alongside your own research and risk tolerance. This is informational content, not investment advice.